Frespaciguat + Placebo
Phase 1Withdrawn 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Coronavirus Disease 2019 (COVID-19)
Conditions
Coronavirus Disease 2019 (COVID-19), Pneumonia, Hypoxemia
Trial Timeline
Jul 7, 2020 → Nov 10, 2020
NCT ID
NCT04425733About Frespaciguat + Placebo
Frespaciguat + Placebo is a phase 1 stage product being developed by Merck for Coronavirus Disease 2019 (COVID-19). The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04425733. Target conditions include Coronavirus Disease 2019 (COVID-19), Pneumonia, Hypoxemia.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05612035 | Phase 2 | Active |
| NCT04425733 | Phase 1 | Withdrawn |
| NCT04370873 | Phase 1 | Completed |
| NCT03744637 | Phase 1 | Completed |
Competing Products
20 competing products in Coronavirus Disease 2019 (COVID-19)